13 results about "Adamantane derivatives" patented technology

The invention belongs to the technical field of drug synthesis, and particularly relates to an adamantane derivative as well as a synthesis method and application thereof. The adamantane derivative comprises an intermediate structural formula I, an intermediate structural formula II and an intermediate structural formula III, and the structural general formula is as follows: Linker is substituted or unsubstituted C6-C10 aroyl, R1 is hydrogen or C1-C6 alkyl, R2 is hydrogen, C1-C6 alkyl or a nitrogen-containing or nitrogen-free structural fragment, or the integral structure of R1R2 is N-substituted heterocyclic pentyl or heterocyclic cyclohexyl. According to the adamantane derivative provided by the invention, an adamantane structure is combined with part of groups of OAB-14, and a parent nucleus structure is changed, so that the drug activity is improved. The invention also provides a synthesis method of the compound, the obtained compound is screened through cell viability research, and the compound has a potential synergistic effect in the aspects of preventing influenza and treating Alzheimer's disease.

The invention provides zanamivir and derivatives thereof, namely adamantane derivative covalent conjugates and application of the zanamivir and the derivatives thereof in resisting influenza viruses. The structure of the zanamivir and the derivative thereof-adamantane derivative covalent conjugate is as shown in formula I in the specification. The invention also provides a method for preparing the zanamivir and the derivative of the zanamivir-adamantane derivative covalent conjugate and a pharmaceutical composition containing the zanamivir and the derivative of the zanamivir-adamantane derivative covalent conjugate. The covalent conjugate provided by the invention not only can improve the pharmacokinetic property of zanamivir, but also has the activity of an M2 ion channel / NA enzyme for inhibiting double targets, can efficiently inhibit influenza viruses, and has relatively high safety.

Provided herein are methods for treating cancer comprising administering to a subject in need thereof an adamantane derivative, or a pharmaceutically acceptable salt thereof, such as rimantadine or amantadine. In some embodiments, the adamantane derivative is PEGylated.

The present application provides a compound, which is an adamantane derivative, comprising a ligand R1 that specifically binds to a target protein (i.e., an estrogen receptor), a ligand R2 that recruits an E3 ubiquitin ligase, and a chemical chain Linker connecting the two parts. Linker is an alkyl chain of varying lengths, wherein the number of carbon atoms in the alkyl chain is n, where 1≤n≤20, and n is an integer; or Linker is a polyethylene glycol chain of varying lengths, wherein the number of oxygen atoms in the polyethylene glycol chain is m, where 1≤m≤5, and m is an integer. The compound provided herein exhibits significant anti-tumor activity through the PROTAC mechanism; in the breast cancer MCF-7 cell line, the proliferation of tumor cells is inhibited by degrading Erα protein, providing a new strategy for the treatment of breast cancer.

The invention provides low-acid-value modified epoxy acrylic resin solder resist ink and a preparation method thereof.The low-acid-value modified epoxy acrylic resin solder resist ink comprises a composition A and a composition B. The composition A comprises acrylic resin, low-acid-value modified epoxy acrylic resin, modified boron nitride, an acrylate monomer, a photoinitiator, an auxiliary and a solvent; the composition B comprises the following components in parts by mass: alicyclic epoxy resin, an auxiliary agent and a solvent; wherein the modified boron nitride is hexagonal boron nitride modified by an adamantane derivative. The low-acid-value modified epoxy acrylic resin solder resist ink is formed by compounding multiple components such as the low-acid-value modified epoxy acrylic resin and the modified boron nitride, so that multiple properties such as stability and dispersity of the ink and strength and adhesive force of a coating film are effectively improved, and the defects and problems in the prior art are solved; the method is of great significance to development of solder resist ink.

The invention provides stretching cooling liquid with a self-cleaning function as well as a preparation method and application thereof, and belongs to the field of metal processing cooling liquid. According to the stretching cooling liquid with the self-cleaning function, the coupling agent, the adamantane derivative and the lubricating agent are matched with one another, the lubricating performance of the stretching cooling liquid can be remarkably improved, adsorption of residues on the surface of a ring-pull can is reduced, the residues can be complexed into the stretching cooling liquid through addition of the complexing agent, and the service life of the ring-pull can is prolonged. The cooling liquid is removed along with stretching; the emulsifier can play a role in stabilizing a system, so that all the components form a uniform and stable system in the carrier matrix, the uniformity is ensured to be kept in the subsequent use process, and meanwhile, the emulsifier can also play a certain lubricating effect to further remove residues; after the components are optimized, a cleaning process in the processing process of the zip-top can can be omitted, the production cost is effectively reduced, the production efficiency is improved, wastewater discharge is reduced, and the zip-top can is more energy-saving and environment-friendly.

The application discloses a polyphenyl-substituted adamantane derivative monomolecular resin represented by formula IA and a preparation method and application thereof. The polyphenyl-substituted adamantane derivative monomolecular resin has good solubility in various polar solvents, is suitable for being made into a film, has a high decomposition temperature, and can well meet the requirements of a photoetching process.

The invention relates to the technical field of biomedical materials, and discloses an injectable biocompatible hydrogel based on dynamic supramolecular assembly, and the hydrogel comprises the following components by weight: 3.0-5.0% of zinc oxide nanocrystalline regenerated cellulose; 3.0%-5.0% of chondroitin sulfate; 1.5% to 2.5% of recombinant human source collagen; 1%-2% of beta-sodium glycerophosphate; 0.7%-1% of a cyclodextrin polymer; 0.4%-0.7% of an adamantane derivative; 0.3% to 0.5% of PEI-DNA nano particles; 0.1% to 0.3% of calcium citrate; 0.1% to 0.2% of sodium alginate microspheres; 0.15%-0.2% of a pH buffer agent; the preparation method comprises the following steps: taking collagen as a raw material, taking sterile deionized water and normal saline as residual components, and adjusting the components through subject-object supramolecular interaction, ionic crosslinking, collagen thermosensitive assembly and a step-by-step mixing process and structure, so that the prepared hydrogel has the advantages of dynamic reversible crosslinking, shear thinning and self-healing synergy, high biocompatibility and controllable degradation rate.

This invention provides a low-acid-value modified epoxy acrylate resin solder resist ink and its preparation method, comprising composition A and composition B. Composition A comprises the following components: acrylic resin, low-acid-value modified epoxy acrylate resin, modified boron nitride, acrylate monomer, photoinitiator, additives, and solvent. Composition B comprises the following components in parts by weight: alicyclic epoxy resin, additives, and solvent. The modified boron nitride is adamantane derivative-modified hexagonal boron nitride. This invention's low-acid-value modified epoxy acrylate resin solder resist ink is a compound of multiple components, including low-acid-value modified epoxy acrylate resin and modified boron nitride, effectively improving the ink's stability, dispersibility, coating strength, adhesion, and other properties. It solves the shortcomings and problems of existing technologies and is of great significance to the development of solder resist inks.

This invention belongs to the technical field of drug synthesis, specifically relating to adamantane derivatives, their synthetic methods, and applications. The adamantane derivatives described in this invention include intermediate structural formulas I, II, and III, as well as structures with the following general formula: Linker is a substituted or unsubstituted C6-C10 aryl group; R1 is hydrogen or a C1-C6 alkyl group; R2 is hydrogen, a C1-C6 alkyl group, or a nitrogen-containing or nitrogen-free structural fragment; or the overall structure of R1R2 is an N-substituted heterocyclopentyl or heterocyclohexyl group. The adamantane derivatives provided by this invention combine the adamantane structure with a portion of the OAB-14 group, altering the core structure and thus improving drug activity. This invention also provides a synthetic method for these derivatives. Through cellular activity studies, the resulting compounds are screened, demonstrating potential synergistic effects in the prevention of influenza and the treatment of Alzheimer's disease.

The invention relates to the technical field of low-dielectric materials, and particularly discloses a BCB alkenyl adamantane derivative, a preparation method thereof and hydride, and the derivative is specifically shown as follows: at least one BCB alkenyl is contained in substituent groups at 1, 3, 5 and 7 positions of adamantane. According to the present invention, with the strategy of introducing the BCB alkenyl group to the adamantane substituent group, the obtained BCB alkenyl adamantane derivative has characteristics of good thermal property and low dielectric property; meanwhile, the number of substituent groups and the number of BCB alkenyl groups on each substituent group are set as parameters capable of being flexibly adjusted, so that the performance of the derivative can be accurately optimized according to actual requirements. Compared with the prior art, pertinent regulation and control of dielectric constants of existing derivatives can be achieved by adjusting the number of substituent groups, the number of BCB alkenyl groups and other groups on the substituent groups, then directional control over the properties of the derivatives is achieved, and the problem that in the prior art, low-dielectric materials in the fields of high-performance PCBs, electronic packaging and the like are met is solved.

The present invention provides novel adamantane derivatives as inhibitors of a focal adhesion kinase, pharmaceutically acceptable salts thereof, stereoisomers thereof, hydrates or solvates thereof, and a pharmaceutical composition comprising same.

The invention discloses a pyrogallol derivative and a preparation method and application thereof, firstly provides pyrogallol derivatives shown as general formulas (A), (B) and (C) or pharmaceutically acceptable salts thereof, and further provides a preparation method of the pyrogallol derivative. Finally, the invention also discloses application of the pyrogallol derivative in preparation of a medicine for preventing or treating coronavirus infection. The pyrogallol derivative can inhibit the activity of SARS-CoV-2 Mpro, wherein R is selected from an adamantane derivative or a bicyclo [1.1. 1] pentane fragment.